The ADA 2027 abstract submission process is a critical pathway for researchers and clinicians to share new findings with the global diabetes community. The American Diabetes Association accepts original research abstracts across all areas of diabetes science, including basic research, translational medicine, clinical trials, epidemiology, health services research, and diabetes technology.
Abstract submission for ADA 2027 is expected to open in the fall of 2026 via the official ADA submission portal. Submitters are encouraged to review the detailed submission guidelines carefully before preparing their abstract. Accepted abstracts may be selected for oral presentations, highlighted poster presentations, or standard poster sessions depending on scientific merit and reviewer scoring.
The ADA employs a rigorous peer-review process for abstract evaluation. Each submission is reviewed by multiple independent experts in the relevant scientific domain. Authors of accepted abstracts are required to register for the conference and present their work in person. The ADA online platform also provides on-demand access to abstract content for registered attendees worldwide following the conference.
Submitting a well-crafted abstract to ADA 2027 offers researchers significant visibility within the global diabetes community. Oral presentations and highlighted posters at the ADA Scientific Sessions frequently attract attention from leading journals, industry partners, and funding agencies. Presenters benefit from direct feedback from world-renowned experts and invaluable networking opportunities.
June 2027
ADA 2027 Abstract Submission Guidelines
June 2027
